Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Hemangiosarcoma

Hemangiosarcoma

Hemangiosarcoma is a malignant tumor originating from the endothelial cells that line blood vessels.
It is a rare and aggresive form of cancer that commonly affects the spleen, liver, and skin in dogs, but can also occur in other species.
Hemangiosarcoma is characterized by rapid growth, early metastasis, and a poor prognosis.
Understanding the molecular mechanisms and identifying effective treatment strategies are active areas of research for this challenging disease.

Most cited protocols related to «Hemangiosarcoma»

1
Hemangiosarcoma Cell Lines VEGFR Inhibition
Cited 8 times
The hemangiosarcoma cell lines Frog, Tucker, Dal-4, Joey, and DD-1 (Table 1) were cultured as described previously [23] (link). Veronica and Emma cell lines were developed as described [23] (link) from splenic and a metastatic brain hemangiosarcomas, respectively, both from Golden Retrievers. For VEGFR inhibition, cells were cultured in the presence of small molecules that selectively inhibit VEGFR kinase (VEGF Receptor Tyrosine Kinase Inhibitor II, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamid, hereafter called “Drug 1”; VEGFR Tyrosine Kinase Inhibitor III, KRN633, N-(2-Chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N′-propylurea, hereafter called “Drug 2”; or VEGF Receptor Kinase Inhibitor IV, 3-(3-Thienyl)-6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine, hereafter called “Drug 3”). The half maximal inhibitory concentrations for VEGFR1 and VEGFR2 for Drugs 1, 2, and 3, respectively are 180 and 20, 170 and 160, and 1.9 and 19. Cells (10,000/well) were plated in duplicate in 96-well microtiter plates and allowed to attach for 16 hr prior to addition of inhibitors over a concentration range from 1 pM to 1 µM. Cells were then cultured for 72 hr, and the number of viable cells was determined using the MTS assay (Promega, Madison, WI). Absorption at 490 nm for each well was averaged, and data normalized to % viability where the mean of wells that received no treatment (0 nm) was considered = 1. The results show the means of two independent experiments for each cell line.
Tamburini B.A., Trapp S., Phang T.L., Schappa J.T., Hunter L.E, & Modiano J.F. (2009). Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed. PLoS ONE, 4(5), e5549.
Full text: Click here
Publication 2009
Biological Assay Brain Cardiac Arrest Cell Lines Cells Hemangiosarcoma inhibitors KRN 633 Pharmaceutical Preparations Phosphotransferases Promega propylurea Psychological Inhibition Pyrimidines Rana Spleen Vascular Endothelial Growth Factor Receptor Vascular Endothelial Growth Factor Receptor-1 Vascular Endothelial Growth Factor Receptor-2 Veronica
2
Canine Hemangiosarcoma Cell Lines
Cited 6 times
Samples used to derive canine hemangiosarcoma cell lines from 10 pet dogs [19] (link), [23] (link), [24] (link) are listed in Table 1. Only two of the dogs whose samples were used for the microarray experiments (Frog and Journey) were related within 5 generations, and they were separated by 3 generations (Frog was Journey's “great aunt”), reducing the likelihood of lineage bias. Cryopreserved cultured cells from the earliest available passages were used for these experiments. Peripheral blood samples collected from healthy dogs or from dogs with cancer prior to the initiation of any therapy (at the time of tumor biopsy) were used as controls. Non-hemangiosarcoma diagnoses included non-Hodgkin lymphoma, melanoma, and osteosarcoma. Blood samples were age and sex-matched to reduce variation. Every sample used for this study was obtained with owner consent through protocols reviewed by appropriate Institutional Animal Care and Use Committees. Samples from healthy pet dogs were obtained as part of routine diagnostic or well-health procedures. Samples from pet dogs with cancer were obtained by the attending veterinarian as part of medically necessary (biopsy) procedures or at the time of necropsy.
Tamburini B.A., Trapp S., Phang T.L., Schappa J.T., Hunter L.E, & Modiano J.F. (2009). Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed. PLoS ONE, 4(5), e5549.
Full text: Click here
Publication 2009
Autopsy Biopsy BLOOD Canis familiaris Cell Lines Cultured Cells Diagnosis Hemangiosarcoma Institutional Animal Care and Use Committees Lymphoma, Non-Hodgkin, Familial Malignant Neoplasms Melanoma Microarray Analysis Neoplasms Osteosarcoma Rana Therapeutics Veterinarian
3
Genetic Analysis of Cartilage Tumors
Cited 4 times
Fresh frozen tumor tissues (n = 60) of 44 patients with multiple cartilage tumors (36 patients with Ollier disease and 8 patients with Maffucci syndrome) (Table 1, Supplementary Table 1) were collected from EuroBoNet consortium (http://www.eurobonet.eu) 8 (link) and the Laboratory of Human Molecular Genetics at the de Duve Institute, UCL (Brussels, Belgium). In addition, paraffin embedded tumor tissues (n = 15) from 12 patients were obtained from the files of the Children's Hospital (Boston, USA). Samples were handled according to the ethical guidelines of the host institution. All samples were coded and the ethical guidelines “Code for Proper Secondary Use of Human Tissue in The Netherlands” (Dutch Federation of Medical Scientific Societies) were followed in all procedures. Chondrosarcoma samples were graded according to Evans et al 56 (link). Normal DNA derived from saliva, blood or muscle was available from 12 patients with Ollier disease. Patients' ages were documented at the time of operation. Demographic and survival data were obtained from the host institutions' patient records.
For comparison with other cartilage tumors, we included DNA from solitary enchondromas (n =9), solitary central chondrosarcomas (n=92), central dedifferentiated chondrosarcomas (n=13), periosteal chondrosarcomas (n=3), 37 peripheral cartilaginous tumors [solitary osteochondroma (n = 11), peripheral chondrosarcomas (n=20), multiple osteochondromas (n=6)], as well as 9 chondromyxoid fibromas, 7 chondroblastomas, and 2 osteochondroma-like lesions of metachondromatosis. Matching blood-derived DNA was also available from 24 cases as controls. Additionally, we included DNA from angiosarcomas (n = 14) since patients with Maffucci syndrome have central cartilage tumors combined with vascular tumors. The angiosarcomas, chondromyxoid fibromas and chondroblastomas were analyzed for IDH1 mutations only. Thus, in total we analyzed 261 tumors from 242 patients.
Pansuriya T.C., van Eijk R., Adamo P.D., van Ruler M.A., Kuijjer M.L., Oosting J., Cleton-Jansen A.M., van Oosterwijk J.G., Verbeke S.L., Meijer D., van Wezel T., Nord K.H., Sangiorgi L., Toker B., Liegl-Atzwanger B., San-Julian M., Sciot R., Limaye N., Kindblom L.G., Daugaard S., Godfraind C., Boon L.M., Vikkula M., Kurek K.C., Szuhai K., French P.J, & Bovée J.V. (2011). Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature genetics, 43(12), 1256-1261.
Publication 2011
BLOOD Cartilage Cartilaginous Exostosis Chondroblastoma Chondrosarcoma Enchondroma Enchondromatosis Fibroma Freezing Hemangiosarcoma Homo sapiens Maffucci Syndrome Metachondromatosis Muscle Tissue Mutation Neoplasms Neoplasms, Vascular Tissue Osteochondromatosis Paraffin Patients Periosteum Saliva Tissues
4
Canine Whole Genome Sequencing Analysis
Cited 3 times
Canine WES and WGS data were downloaded from the Sequence Read Archive (SRA) database, including PRJNA489159 (mammary tumor), PRJEB12081 (oral melanoma), PRJNA579792 (glioma), PRJNA552034 (hemangiosarcoma), PRJNA247493 (osteosarcoma, lymphoma, and unclassified) and others listed in Supplementary Data 1. We also obtained other information from relevant publications11 (link)–20 (link),24 (link),41 (link),42 (link).
Canine genome canFam3.1 and gene annotation canFam3 1.99 GTF were downloaded from the Ensembl database. Known canine germline base substitutions and small indels (55,447,895 total) were combined from (1) Ensembl canine dbSNP, canFam3; (2) the DoGSD database43 (link) and (3) a published study44 (link).
Alsaihati B.A., Ho K.L., Watson J., Feng Y., Wang T., Dobbin K.K, & Zhao S. (2021). Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nature Communications, 12, 4670.
Full text: Click here
Publication 2021
Animal Mammary Neoplasms Canis familiaris Gene Annotation Genome Germ Line Glioma Hemangiosarcoma INDEL Mutation Lymphoma Melanoma Osteosarcoma
5
Propranolol Inhibits Tumor Growth in CAM and Mouse Models
Cited 3 times
SVR chorioallantoic membrane (CAM) tumors were grown using the gelatin sponge-chorioallantoic membrane (CAM) assay as previously described [28] (link). An isotonic saline sham (N = 4 eggs) or 100 µM propranolol (N = 3 eggs) was added daily directly onto the tumors every two days, and tumors were collected 6 days post implantation. Mouse angiosarcoma tumors were generated by subcutaneous injection of 1×106 SVR cells into the dorsolateral flank of 4 week old female mice as previously described [29] (link). Mice were treated with sham (isotonic saline; N = 15) or propranolol (10 mg/ml; N = 17) via intraperitoneal injections every 2 days. When the sham tumors reached approximately 1 cm in diameter, the tumors were collected. Numerical data presented for all tumor experiments is the average of at least three biological replicates +/− the standard deviation (for the CAM assays) or the standard error of the mean (for the mouse angiosarcoma tumor assays). Statistical significance was determined using Student’s t-test (P<0.05).
Stiles J.M., Amaya C., Rains S., Diaz D., Pham R., Battiste J., Modiano J.F., Kokta V., Boucheron L.E., Mitchell D.C, & Bryan B.A. (2013). Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and Angiosarcoma. PLoS ONE, 8(3), e60021.
Full text: Click here
Publication 2013
Biological Assay Biopharmaceuticals Cells Eggs Gelatins Hemangiosarcoma Injections, Intraperitoneal Membrane, Chorioallantoic Mus Neoplasms Neoplasms, Experimental Ovum Implantation Porifera Propranolol Saline Solution Student Subcutaneous Injections Woman

Most recents protocols related to «Hemangiosarcoma»

1
Comparative Immunohistochemical Profiling of Bladder Lesions
Staining was compared among UC, inflammatory non-neoplastic (cystitis), and normal urinary bladder samples. A histologically confirmed canine metastatic hemangiosarcoma served as a positive control for VEGFR2; a canine liposarcoma served as a positive control for KIT; a canine squamous cell carcinoma served as a positive control for PDGFR-β; and a canine mesenchymal neoplasm was used as a positive control for CDK4 (Suppl. Figs. 1–4). A negative control that omitted incubation with the primary antibody (antibody diluent with no antibody) was included for each sample.
Samples were evaluated for urothelial expression of VEGFR2, KIT, PDGFR-β, and CDK4 in an anonymized study by 3 veterinary pathologists, each from a different institution. A qualitative immunohistochemical assessment was performed to evaluate staining intensity. As described previously,32
staining intensity was assessed over the whole sample at 200 × magnification (0 = none, 1 = mild, 2 = moderate, 3 = intense). Staining distribution (% urothelial cells affected) was evaluated semi-quantitatively over 10 hpfs at 400 × magnification (0 = no staining, 1 = >0% to <10% positive, 2 = ≥10% to <25% positive, 3 = ≥25% to 50% positive, 4 = ≥50% to <75% positive, 5 = ≥75% positive). To calculate a score for every sample, the average scores were taken and called the standardized score. After averaging the 10 selected fields, a final immunohistochemical score for each sample was calculated by multiplying the intensity (qualitative) standardized score by the staining distribution (semi-quantitative) standardized score, as described previously.3 (link),22 (link)
Setyo L.C., Donahoe S.L., Shearer P.L., Wang P, & Krockenberger M.B. (2023). Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma. Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 35(2), 109-115.
Publication 2023
Canis familiaris Cells Cystitis Figs Hemangiosarcoma Immunoglobulins Inflammation Liposarcoma Mesenchyma Neoplasms Pathologists Platelet-Derived Growth Factor beta Receptor Squamous Cell Carcinoma Urinary Bladder Urothelium Vascular Endothelial Growth Factor Receptor-2
2
Scalp Angiosarcoma Surgical Outcomes
A retrospective chart review was conducted on patients managed at Asan Medical Center with a histologically confirmed diagnosis of cutaneous angiosarcoma of the scalp. We selected cases that had been amenable for surgical resection and were treated between 2005 and 2021 with tumor located primarily in the scalp. Patients with a distant metastasis at presentation or regional lymph node metastasis were included if surgical resection and reconstruction had been performed for palliative purposes. Patients with nonscalp tumor location, who refused surgical excision, or who were managed after the inclusion period were excluded from the analysis. We received institutional review board approval for this study.
A detailed, comprehensive history was taken from all patients, who also underwent thorough physical examinations, blood testing, and radiological imaging. The diagnosis of cutaneous angiosarcoma in each case was confirmed through a histopathological examination for the following markers: cluster of differentiation (CD) 31, CD34, factor VIII-related antigen, von Willebrand factor II, podoplanin (D2–40), and nuclear protein marker of proliferation (MKi-67 or KI-67). The data collected for each patient included age at the time of diagnosis, gender, history of smoking, comorbid conditions, extent of lymph node involvement, recurrence and metastasis, treatment modality and reconstructive method applied, surgical margin, postoperative complications (if any), information on last follow-up, and time of death.
Kaplan-Meier curves were used to analyze overall survival, and any differences between patient groups were tested using multivariate analysis and the log rank test to evaluate different factors that may impact locoregional recurrence, metastasis, and overall survival. These variables included tumor size, resection size, satellite lesions at presentation, nodal disease, lymph node dissection, surgical margin status, and mode of therapy (single or combined). Overall survival was defined as the time from diagnosis to death, regardless of the cause. Recurrence was defined as the time from surgical treatment until either local or regional recurrence was documented.
Alharbi A., Kim Y.C., AlShomer F, & Choi J.W. (2023). Utility of Multimodal Treatment Protocols in the Management of Scalp Cutaneous Angiosarcoma. Plastic and Reconstructive Surgery Global Open, 11(3), e4827.
Publication 2023
Diagnosis Ethics Committees, Research Factor VIII-Related Antigen Gender Hemangiosarcoma Lymph Node Excision Lymph Node Metastasis Neoplasm Metastasis Neoplasms Neoplasms by Site Nodes, Lymph Nuclear Protein Operative Surgical Procedures Patients Physical Examination Postoperative Complications Prothrombin Reconstructive Surgical Procedures Recurrence Scalp Surgical Margins Therapeutics X-Rays, Diagnostic
3
Angiosarcoma Tumor Tissue Collection
Anonymized tumor tissues from angiosarcoma patients undergoing surgery were collected with informed consent. Ethical approval was obtained from the local certified Medical Ethics Committee of the Radboudumc, Nijmegen, The Netherlands (File number 2016-2686). All experiments were performed in accordance with relevant guidelines and regulations.
Versleijen-Jonkers Y.M., Hillebrandt-Roeffen M.H., Weidema M.E., Mooren J., von Rhein D.T., de Bitter T.J., Kroeze L.I., Desar I.M, & Flucke U.E. (2023). Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5). Scientific Reports, 13, 2653.
Full text: Click here
Publication 2023
Hemangiosarcoma Neoplasms Operative Surgical Procedures Patients Regional Ethics Committees Tissues
4
Rare Pulmonary Sarcoma Epidemiology
Inclusion criteria was performed according to the factors such as (1) the diagnosis time, 1998 to 2015, (2) the primary sites of PPS in lung and bronchus (C34.0-C34.9), (3) ICD-O-3 histological type confirmed by pathology: epithelioid hemangioendothelioma, hemangiosarcoma, pleuropulmonary blastoma, chondroma, monophasic/biphasic synovial sarcoma, pulmonary artery/vein sarcoma, and (4) exact follow-up information.
Exclusion criteria were executed according to the factors including (1) non-pathologically positive data and (2) unknown survival time.
Gu H., Song R., Beeraka N.M., Li T., Zhao D., Liu J, & Fan R. (2023). SEER-Based Survival Nomogram (1998-2015) Based on ‘Stage, Lymph Node Dissection, Tumor Size and Degree of Differentiation, and Therapies’ for Prognosis of Primary Pulmonary Sarcoma. Technology in Cancer Research & Treatment, 22, 15330338221150732.
Publication 2023
Arteries Bronchi Chondroma Diagnosis Epithelioid Hemangioendothelioma Hemangiosarcoma Lung Pleuropulmonary blastoma Pulmonary Artery Sarcoma Synovial Sarcoma Veins Veins, Pulmonary
5
Bioinformatic Workflow for Sarcoma Transcriptome Analysis
Our bioinformatic workflow was based on a primary quality check with FastQC and MultiQC to ensure read quality was acceptable and transcriptomes were comparable among samples [10 ,11 (link)]. Secondly, reads were mapped on the human genome to identify expressed genes. To determine transcript abundance, read quantification was performed obtaining raw counts. Subsequently, to ensure comparability, raw counts were normalized as counts per million (CPM) and transcripts per million (TPM), which were required for differential gene expression (DGE) and principal component analysis (PCA), respectively.
In detail, STAR was adopted to map paired reads on the reference human genome hg38 [12 (link)]; while duplicates’ removal, sorting, and indexing were performed with Samtools [13 (link)]. Gene expression was quantified and normalized as CPM and TPM, after obtaining raw gene counts with the Python package HTseq-count [14 (link)]. Starting from CPM, differentially expressed genes (q-value < 0.05, FDR-corrected) between either the leiomyosarcoma or osteosarcoma case and the group including angiosarcomas (CS6 and CS7) and intimal sarcomas (CS1, CS2, CS3, CS4 and CS5) were identified with the R-bioconductor package edgeR [15 (link)]. Using the R package prcomp [16 (link)] instead, TPM were employed to perform PCA, which also included intimal sarcomas (n = 5) and angiosarcomas (n = 2).
Additionally, gene fusion detection and small variant calling combined with variant annotation via Nirvana were performed on BaseSpace, an Illumina webtool (http://euc1.sh.basespace.illumina.com/ accessed on 4 June 2022). For gene-fusion detection, protein-coding and lncRNA genes were included to reduce false positives.
The vcf output files were filtered to include only stop gain/splice donor/splice acceptor/splice region/frameshift indels/inframe deletion/inframe insertion/initiator codon/ATG loss/missense mutations predicted as deleterious or probably damaging by SIFT predictor, with a GnomAD Frequency < 0.01, a QC metric quality ≥ 30, a total read depth > 14, an alt allele depth > 3, and a variant read frequency > 0.15. Finally, only genes belonging to Tier 1 of the Cancer Gene Census list (https://cancer.sanger.ac.uk/census accessed on 4 June 2022) were considered for further analysis. Sequencing data of both samples were analyzed using the DRAGEN RNA app (version 3.10.4).
Gozzellino L., Nannini M., Pizzi C., Leone O., Corti B., Indio V., Baldovini C., Paolisso P., Foà A., Pacini D., Folesani G., Schipani A., Costa A., Pasquinelli G., Pantaleo M.A, & Astolfi A. (2023). Genomic Characterization of Rare Primary Cardiac Sarcoma Entities. Diagnostics, 13(2), 214.
Full text: Click here
Publication 2023
Alleles Codon, Initiator Deletion Mutation Frameshift Mutation Gene, Cancer Gene Expression Gene Fusion Genes Genome, Human Hemangiosarcoma Homo sapiens INDEL Mutation Leiomyosarcoma Malignant Neoplasms Osteosarcoma Proteins Python RNA, Long Untranslated Sarcoma Tissue Donors Transcriptome Tunica Intima

Top products related to «Hemangiosarcoma»

1
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
2
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
3
Hiseq 2000 by Illumina
Sourced in United States, China, Germany, United Kingdom, Hong Kong, Canada, Switzerland, Australia, France, Japan, Italy, Sweden, Denmark, Cameroon, Spain, India, Netherlands, Belgium, Norway, Singapore, Brazil
The HiSeq 2000 is a high-throughput DNA sequencing system designed by Illumina. It utilizes sequencing-by-synthesis technology to generate large volumes of sequence data. The HiSeq 2000 is capable of producing up to 600 gigabases of sequence data per run.
4
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
5
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
6
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
7
Quantitect reverse transcription kit by Qiagen
Sourced in Germany, United States, United Kingdom, Japan, Netherlands, Canada, China, Australia, Italy, France, Spain, India, Switzerland, Belgium, Norway, Sweden, Denmark
The QuantiTect Reverse Transcription Kit is a laboratory tool designed for the reverse transcription of RNA into complementary DNA (cDNA). It enables the conversion of RNA samples into cDNA, which can then be used for various downstream applications, such as real-time PCR or gene expression analysis.
8
Murine svr angiosarcoma cells by American Type Culture Collection
Murine SVR angiosarcoma cells are a well-characterized cell line derived from a spontaneous angiosarcoma in a C57BL/6J mouse. These cells exhibit characteristics of endothelial cells and can be used for in vitro studies related to angiogenesis and vascular biology.
9
Endothelial cell growth medium mv by PromoCell
Sourced in Germany
Endothelial Cell Growth Medium MV is a serum-free, low-protein medium designed for the cultivation of primary human endothelial cells. The medium contains the necessary growth factors and supplements to support the proliferation and maintenance of endothelial cells in vitro.
10
Dulbecco s modified eagle s medium by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Japan, Canada, France, Australia, Switzerland, Italy, Spain, India, Ireland, Israel, Austria, Brazil, Sweden, Hong Kong, Netherlands, Macao, Belgium, New Zealand, Holy See (Vatican City State), Argentina
Dulbecco's modified Eagle's medium (DMEM) is a cell culture medium formulated to support the growth and maintenance of various cell types. It provides a balanced salt solution, amino acids, vitamins, and other nutrients required for cell proliferation and survival. DMEM is a widely used medium in cell biology research and applications.

More about "Hemangiosarcoma"

Hemangiosarcoma is a rare and aggressive form of cancer that originates from the endothelial cells lining blood vessels.
It commonly affects the spleen, liver, and skin in dogs, but can also occur in other species.
This malignant tumor is characterized by rapid growth, early metastasis, and a poor prognosis.
Understanding the molecular mechanisms and identifying effective treatment strategies for hemangiosarcoma are active areas of research.
Researchers often utilize various cell culture techniques and animal models to study this challenging disease.
Some key components used in these studies include Streptomycin, Penicillin, HiSeq 2000 sequencing technology, L-glutamine, fetal bovine serum (FBS), Penicillin/streptomycin antibiotics, QuantiTect Reverse Transcription Kits, Murine SVR angiosarcoma cells, Endothelial Cell Growth Medium MV, and Dulbecco's modified Eagle's medium.
Advancements in research methodologies, such as those enabled by PubCompare.ai, are revolutionizing the field of hemangiosarcoma studies.
The platform's AI-driven comparisons help researchers identify the most relevant protocols and products, enhancing reproducibility and accuracy in their investigations.
This data-driven approach empowers researchers to make informed decisions and accelerate the development of effective treatment strategies for this aggressive form of cancer.